Literature DB >> 10704737

Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9.

M J Scanlan1, N K Altorki, A O Gure, B Williamson, A Jungbluth, Y T Chen, L J Old.   

Abstract

In an effort to define new cancer-testis (CT) genes, we investigated whether BRDT, a testis-restricted member of the RING3 family of transcriptional regulators, is also expressed in cancer. Standard RT-PCR expression analysis detected BRDT transcripts in 12 of 47 cases of non-small cell lung cancer and single cases of both squamous cell carcinoma of the head and neck (1/12) and esophagus (1/12) but not in melanoma or in cancers of the colon, breast, kidney and bladder. Typing of 33 non-small cell lung cancers for coexpression of a panel of CT antigens revealed a high incidence (60%) of MAGE-3 mRNA expression, followed by MAGE-1 (36%), CT7/MAGE-C1 (30%), CT10 (30%), SSX4 (23%), BRDT (21%), NY-ESO-1 (21%) and HOM-MEL-40/SSX2 (15%). The coexpression pattern of these antigens provides a foundation for developing a polyvalent lung cancer vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704737     DOI: 10.1016/s0304-3835(99)00385-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  39 in total

1.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.

Authors:  Amanda P Liggins; Seah H Lim; Elizabeth J Soilleux; Karen Pulford; Alison H Banham
Journal:  Cancer Immun       Date:  2010-08-23

Review 2.  Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.

Authors:  Thinle Chodon; Amit A Lugade; Sebastiano Battaglia; Kunle Odunsi
Journal:  Hematol Oncol Clin North Am       Date:  2018-10-01       Impact factor: 3.722

Review 3.  Biological function and histone recognition of family IV bromodomain-containing proteins.

Authors:  Jonathan T Lloyd; Karen C Glass
Journal:  J Cell Physiol       Date:  2017-06-13       Impact factor: 6.384

4.  Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.

Authors:  Bo Yin; Yu Zeng; Xiaosong Wang; Gang Liu; Mo Zhang; Yongsheng Song
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.

Authors:  T Ono; T Kurashige; N Harada; Y Noguchi; T Saika; N Niikawa; M Aoe; S Nakamura; T Higashi; A Hiraki; H Wada; H Kumon; L J Old; E Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

6.  Expression, purification and serological analysis of hepatocellular carcinoma associated antigen HCA587 in insect cells.

Authors:  Bing Li; Hong-Yan Wu; Xiao-Ping Qian; Yan Li; Wei-Feng Chen
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 7.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

8.  Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities.

Authors:  Li Liu; Yongxia Zhu; Zhihao Liu; Tinghong Ye; Weiqiong Zuo; Cuiting Peng; Kunjie Xiao; Ningyu Wang; Luoting Yu
Journal:  Mol Divers       Date:  2016-11-17       Impact factor: 2.943

9.  Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model.

Authors:  Guilan Shi; Huiru Wang; Xiufen Zhuang
Journal:  Oncol Lett       Date:  2015-11-13       Impact factor: 2.967

10.  Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein.

Authors:  Christophe Pivot-Pajot; Cécile Caron; Jérôme Govin; Alexandre Vion; Sophie Rousseaux; Saadi Khochbin
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.